Diabetes drug linked to cancer- Pharma firms fined

2014 Research

Pharmaceutical firm Takeda has been fined $6 billion for covering up health risks relating to bladder cancer associated with their popular type-2 diabetes drug ACTOS. Takeda’s partner, Pharma company Eli Lilly was fined $3 billion for its part in the cover up.


The firms were involved in a US court case where the prosecution alleged the companies to be guilty of destroying and deleting thousands of documents relating to cancer, side-effects and other health issues for Actos, or pioglitazone.


Worryingly, the drug has been used for 15 years since1999 and has achieved over $16 billion in sales. 


 

2014 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.